- Home
- RCKY vs NTHI Comparison
RCKY vs NTHI Comparison
Compare RCKY & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKY | NTHI |
|---|---|---|
| Founded | 1932 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.3M | 193.2M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKY | NTHI |
|---|---|---|
| Price | $32.81 | $8.89 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $40.00 | N/A |
| AVG Volume (30 Days) | 30.0K | ★ 51.3K |
| Earning Date | 02-24-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 53.66 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $470,314,000.00 | $59,990.00 |
| Revenue This Year | $7.09 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $11.93 | $3.20 |
| 52 Week High | $34.36 | $25.00 |
Technical Indicators
Market Signals| Indicator | RCKY | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 63.00 | 50.28 |
| Support Level | $31.91 | $7.99 |
| Resistance Level | $34.36 | $10.19 |
| Average True Range (ATR) | 1.13 | 0.82 |
| MACD | 0.31 | -0.06 |
| Stochastic Oscillator | 76.00 | 32.54 |
Price Performance
Historical ComparisonAbout RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).